vs
Side-by-side financial comparison of Biogen (BIIB) and Liberty Media Corp (FWONA). Click either name above to swap in a different company.
Biogen is the larger business by last-quarter revenue ($2.3B vs $1.6B, roughly 1.4× Liberty Media Corp). Liberty Media Corp runs the higher net margin — 20.7% vs -2.1%, a 22.8% gap on every dollar of revenue. On growth, Liberty Media Corp posted the faster year-over-year revenue change (150.7% vs -7.1%). Biogen produced more free cash flow last quarter ($468.0M vs $62.0M). Over the past eight quarters, Biogen's revenue compounded faster (-0.2% CAGR vs -23.5%).
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis ; nusinersen (Spinraza) for the treatment of spinal muscular atrophy ; omaveloxolone (Skyclarys) for ...
Liberty Media Corporation is an American mass media company founded by John C. Malone in 1991. The company has two divisions, represented by separate tracking stocks, reflecting its ownership stakes in the Formula One Group and Live Nation Entertainment. As of 2025, Liberty Media owned three global motorsport businesses in the form of Formula One, MotoGP and World Superbikes.
BIIB vs FWONA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.3B | $1.6B |
| Net Profit | $-48.9M | $333.0M |
| Gross Margin | 78.3% | — |
| Operating Margin | -2.5% | 14.0% |
| Net Margin | -2.1% | 20.7% |
| Revenue YoY | -7.1% | 150.7% |
| Net Profit YoY | -118.3% | 193.8% |
| EPS (diluted) | $-0.35 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.3B | $1.6B | ||
| Q3 25 | $2.5B | $1.1B | ||
| Q2 25 | $2.6B | $1.3B | ||
| Q1 25 | $2.4B | $447.0M | ||
| Q4 24 | $2.5B | $-3.2B | ||
| Q3 24 | $2.5B | $911.0M | ||
| Q2 24 | $2.5B | $3.2B | ||
| Q1 24 | $2.3B | $2.7B |
| Q4 25 | $-48.9M | $333.0M | ||
| Q3 25 | $466.5M | $13.0M | ||
| Q2 25 | $634.8M | $204.0M | ||
| Q1 25 | $240.5M | $5.0M | ||
| Q4 24 | $266.7M | $-355.0M | ||
| Q3 24 | $388.5M | $-2.4B | ||
| Q2 24 | $583.6M | $457.0M | ||
| Q1 24 | $393.4M | $203.0M |
| Q4 25 | 78.3% | — | ||
| Q3 25 | 73.4% | — | ||
| Q2 25 | 77.1% | — | ||
| Q1 25 | 74.1% | — | ||
| Q4 24 | 76.2% | — | ||
| Q3 24 | 74.1% | — | ||
| Q2 24 | 77.8% | — | ||
| Q1 24 | 76.3% | — |
| Q4 25 | -2.5% | 14.0% | ||
| Q3 25 | 22.0% | 13.7% | ||
| Q2 25 | 28.1% | 20.4% | ||
| Q1 25 | 12.8% | -15.9% | ||
| Q4 24 | 11.9% | — | ||
| Q3 24 | 18.3% | 11.7% | ||
| Q2 24 | 28.3% | 16.7% | ||
| Q1 24 | 20.3% | 18.3% |
| Q4 25 | -2.1% | 20.7% | ||
| Q3 25 | 18.4% | 1.2% | ||
| Q2 25 | 24.0% | 15.2% | ||
| Q1 25 | 9.9% | 1.1% | ||
| Q4 24 | 10.9% | 11.2% | ||
| Q3 24 | 15.8% | -259.9% | ||
| Q2 24 | 23.7% | 14.4% | ||
| Q1 24 | 17.2% | 7.4% |
| Q4 25 | $-0.35 | — | ||
| Q3 25 | $3.17 | — | ||
| Q2 25 | $4.33 | — | ||
| Q1 25 | $1.64 | — | ||
| Q4 24 | $1.82 | — | ||
| Q3 24 | $2.66 | — | ||
| Q2 24 | $4.00 | — | ||
| Q1 24 | $2.70 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $1.1B |
| Total DebtLower is stronger | $6.3B | $5.1B |
| Stockholders' EquityBook value | $18.3B | $7.8B |
| Total Assets | $29.4B | $15.4B |
| Debt / EquityLower = less leverage | 0.34× | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.1B | ||
| Q3 25 | — | $1.6B | ||
| Q2 25 | — | $3.4B | ||
| Q1 25 | — | $3.1B | ||
| Q4 24 | — | $3.0B | ||
| Q3 24 | — | $3.1B | ||
| Q2 24 | — | $2.1B | ||
| Q1 24 | — | $1.7B |
| Q4 25 | $6.3B | $5.1B | ||
| Q3 25 | $6.3B | $7.0B | ||
| Q2 25 | $6.3B | $4.8B | ||
| Q1 25 | $4.5B | $4.6B | ||
| Q4 24 | $6.3B | $4.5B | ||
| Q3 24 | $4.5B | $4.4B | ||
| Q2 24 | $6.3B | $15.0B | ||
| Q1 24 | $6.3B | $15.4B |
| Q4 25 | $18.3B | $7.8B | ||
| Q3 25 | $18.2B | $7.4B | ||
| Q2 25 | $17.6B | $7.3B | ||
| Q1 25 | $17.0B | $7.0B | ||
| Q4 24 | $16.7B | $7.0B | ||
| Q3 24 | $16.4B | $7.4B | ||
| Q2 24 | $15.9B | $17.1B | ||
| Q1 24 | $15.2B | $16.6B |
| Q4 25 | $29.4B | $15.4B | ||
| Q3 25 | $29.2B | $17.8B | ||
| Q2 25 | $28.3B | $13.8B | ||
| Q1 25 | $28.0B | $13.3B | ||
| Q4 24 | $28.0B | $12.9B | ||
| Q3 24 | $28.3B | $13.2B | ||
| Q2 24 | $26.8B | $42.6B | ||
| Q1 24 | $26.6B | $42.4B |
| Q4 25 | 0.34× | 0.66× | ||
| Q3 25 | 0.35× | 0.95× | ||
| Q2 25 | 0.36× | 0.65× | ||
| Q1 25 | 0.27× | 0.65× | ||
| Q4 24 | 0.38× | 0.65× | ||
| Q3 24 | 0.28× | 0.59× | ||
| Q2 24 | 0.40× | 0.88× | ||
| Q1 24 | 0.41× | 0.93× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $511.9M | $123.0M |
| Free Cash FlowOCF − Capex | $468.0M | $62.0M |
| FCF MarginFCF / Revenue | 20.5% | 3.9% |
| Capex IntensityCapex / Revenue | 1.9% | 3.8% |
| Cash ConversionOCF / Net Profit | — | 0.37× |
| TTM Free Cash FlowTrailing 4 quarters | $2.1B | $789.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $511.9M | $123.0M | ||
| Q3 25 | $1.3B | $173.0M | ||
| Q2 25 | $160.9M | $231.0M | ||
| Q1 25 | $259.3M | $381.0M | ||
| Q4 24 | $760.9M | $-23.0M | ||
| Q3 24 | $935.6M | $182.0M | ||
| Q2 24 | $625.8M | $752.0M | ||
| Q1 24 | $553.2M | $395.0M |
| Q4 25 | $468.0M | $62.0M | ||
| Q3 25 | $1.2B | $170.0M | ||
| Q2 25 | $134.3M | $209.0M | ||
| Q1 25 | $222.2M | $348.0M | ||
| Q4 24 | $721.6M | $-46.0M | ||
| Q3 24 | $900.6M | $-153.0M | ||
| Q2 24 | $592.3M | $566.0M | ||
| Q1 24 | $507.3M | $194.0M |
| Q4 25 | 20.5% | 3.9% | ||
| Q3 25 | 48.4% | 15.7% | ||
| Q2 25 | 5.1% | 15.6% | ||
| Q1 25 | 9.1% | 77.9% | ||
| Q4 24 | 29.4% | 1.4% | ||
| Q3 24 | 36.5% | -16.8% | ||
| Q2 24 | 24.0% | 17.9% | ||
| Q1 24 | 22.1% | 7.1% |
| Q4 25 | 1.9% | 3.8% | ||
| Q3 25 | 1.8% | 0.3% | ||
| Q2 25 | 1.0% | 1.6% | ||
| Q1 25 | 1.5% | 7.4% | ||
| Q4 24 | 1.6% | -0.7% | ||
| Q3 24 | 1.4% | 36.8% | ||
| Q2 24 | 1.4% | 5.9% | ||
| Q1 24 | 2.0% | 7.3% |
| Q4 25 | — | 0.37× | ||
| Q3 25 | 2.73× | 13.31× | ||
| Q2 25 | 0.25× | 1.13× | ||
| Q1 25 | 1.08× | 76.20× | ||
| Q4 24 | 2.85× | — | ||
| Q3 24 | 2.41× | — | ||
| Q2 24 | 1.07× | 1.65× | ||
| Q1 24 | 1.41× | 1.95× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BIIB
| Products | $1.7B | 73% |
| Tysabri Product | $244.5M | 11% |
| AVONEX | $119.2M | 5% |
| SKYCLARYS | $88.9M | 4% |
| Alzheimers Collaboration | $47.1M | 2% |
| IMRALDI | $43.5M | 2% |
| TECFIDERA | $36.9M | 2% |
| PLEGRIDY | $24.7M | 1% |
| QALSODY | $7.8M | 0% |
| BYOOVIZ | $4.3M | 0% |
FWONA
| Formula One | $1.4B | 87% |
| Product Service Or Other | $131.0M | 8% |
| Other | $77.0M | 5% |
